- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 699-713 of
1,122 results
2462 Exhibit: EX2462 US Food Drug Administration, DrugsFDA, Qtern
Document
IPR2023-00724, No. 2462 Exhibit - EX2462 US Food Drug Administration, DrugsFDA, Qtern (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2060 Exhibit: EX2060 Rosenstock, J, et al, “The Fate of Taspoglutide, a Weekly GL...
Document
IPR2023-00724, No. 2060 Exhibit - EX2060 Rosenstock, J, et al, “The Fate of Taspoglutide, a Weekly GLP 1 Receptor Agonist, Versus Twice Daily Exenatide for Type 2 Diabetes,” Diabetes Care...
|
|
Cite Document
2503 Exhibit: EX2503 Novo Nordisk, Financial report for the period 1 January 2020...
Document
IPR2023-00724, No. 2503 Exhibit - EX2503 Novo Nordisk, Financial report for the period 1 January 2020 to 30 June 2020 Aug 6, 2020 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2055 Exhibit: EX2055 Declaration of Michael J Blaha, MD
Document
IPR2023-00724, No. 2055 Exhibit - EX2055 Declaration of Michael J Blaha, MD (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2359 Exhibit: EX2359 Moses, RG, Combination Therapy for Patients with Type 2 Di...
Document
IPR2023-00724, No. 2359 Exhibit - EX2359 Moses, RG, Combination Therapy for Patients with Type 2 Diabetes Repaglinide in Combination with Metformin, Overview of Oral Antidiabetic Medica...
|
|
Cite Document
2394 Exhibit: EX2394 Mansfield, C, et al, Patient Preferences for Attributes of Type...
Document
IPR2023-00724, No. 2394 Exhibit - EX2394 Mansfield, C, et al, Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain An Online Discrete Choice Expe...
|
|
Cite Document
2010 Exhibit: EX2010 Expert Declaration of Julio Rosenstock, MD
Document
IPR2023-00724, No. 2010 Exhibit - EX2010 Expert Declaration of Julio Rosenstock, MD (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2418 Exhibit: EX2418 US Food Drug Administration, DrugsFDA, Bydureon®
Document
IPR2023-00724, No. 2418 Exhibit - EX2418 US Food Drug Administration, DrugsFDA, Bydureon® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2401 Exhibit: EX2401 US Food Drug Administration, DrugsFDA, Janumet®
Document
IPR2023-00724, No. 2401 Exhibit - EX2401 US Food Drug Administration, DrugsFDA, Janumet® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2441 Exhibit: EX2441 Jardiance® Prescribing Information rev Dec 2016
Document
IPR2023-00724, No. 2441 Exhibit - EX2441 Jardiance® Prescribing Information rev Dec 2016 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2357 Exhibit: EX2357 National Institute of Diabetes and Digestive Kidney Diseases...
Document
IPR2023-00724, No. 2357 Exhibit - EX2357 National Institute of Diabetes and Digestive Kidney Diseases, “Type 2 Diabetes,” httpswwwniddknihgovhealth informationdiabetesoverviewwhat is dia...
|
|
Cite Document
2420 Exhibit: EX2420 Bydureon® BCISE™ Prescribing Information rev Oct 2017
Document
IPR2023-00724, No. 2420 Exhibit - EX2420 Bydureon® BCISE™ Prescribing Information rev Oct 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2510 Exhibit: EX2510 Novo Nordisk, Financial report for the period 1 January 2022...
Document
IPR2023-00724, No. 2510 Exhibit - EX2510 Novo Nordisk, Financial report for the period 1 January 2022 to 31 March 2022 Apr 29, 2022 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2015 Exhibit: EX2015 Shaman, A, et al, “Effect of the Glucagon Like Peptide 1 Rec...
Document
IPR2023-00724, No. 2015 Exhibit - EX2015 Shaman, A, et al, “Effect of the Glucagon Like Peptide 1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2...
|
|
Cite Document
2098 Exhibit: EX2098 Jha, KK, et al, Transitioning to GLP 1 RAs and SGLT2 Inhibit...
Document
IPR2023-00724, No. 2098 Exhibit - EX2098 Jha, KK, et al, Transitioning to GLP 1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes, Curr Athe...
|
|
Cite Document
